Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 3
Submit an article Journal homepage
737
Views
20
CrossRef citations to date
0
Altmetric
Reviews

Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease

Maliheh GhadiriRespiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Sydney, NSW, AustraliaCorrespondence[email protected]
,
Paul M YoungRespiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Sydney, NSW, Australia
&
Daniela TrainiRespiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Sydney, NSW, Australia
Pages 375-387 | Received 07 Oct 2015, Accepted 20 Nov 2015, Published online: 15 Dec 2015

References

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

•• This review has shown the progress in cell-based therapy for lung diseases.

•• This review covers different approaches in the cell-based therapy for lung diseases.

  • Myllärniemi M, Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. European Clin Resp J. 2015;2015:2.
  • Israel-Biet D, Juvin K, Tran KD, et al. Idiopathic pulmonary fibrosis: diagnosis and treatment in 2013. Rev Pneumol Clin. 2014;70:108–117.
  • Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J. 2007;30:835–839.
  • Nogee LM, Dunbar AE, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. New Engl J Med. 2001;344:573–579.
  • Bullard JE, Nogee LM. Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatr Res. 2007;62:176–179.
  • Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med. 2013;64:265–276.

• This is about the latest molecular mechanism involved in IPF disease.

  • Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1:369–376.
  • Kropski JA, Lawson WE, Blackwell TS. Right place, right time: the evolving role of herpesvirus infection as a “second hit” in idiopathic pulmonary fibrosis. Am J Physiol-Lung C. 2012;302:L441–L444.
  • Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21:355–361.
  • Margaritopoulos GA, Giannarakis I, Siafakas NM, et al. An update on idiopathic pulmonary fibrosis. Panminerva Med. 2013;55:109–120.
  • Raghu G, Rochwerg B, Zhang Y, et al. vol 192, pg e3, 2015. An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Resp Crit Care. 2015;192:644–644.

•• This is an updated guideline in IPF therapy.

  • Uzunhan Y, Nunes H, Gille T, et al. Innovative therapeutics for idiopathic pulmonary fibrosis. Presse Medicale. 2011;40:1100–1112.
  • Ahluwalia N, Shea B, Tager A. New therapeutic targets in idiopathic pulmonary fibrosis aiming to rein in runaway wound-healing responses. Am J Resp Crit Care. 2014;190:867–878.
  • Marshall RP, Gohlke P, Chambers RC, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol-Lung C. 2004;286:L156–L164.
  • Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem. 2010;53:7715–7730.
  • MacKinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-beta 1-driven lung fibrosis by galectin-3. Am J Resp Crit Care. 2012;185:537–546.
  • Wang HD, Yamaya M, Okinaga S, et al. Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. Am J Resp Crit Care. 2002;165:406–411.
  • Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Resp Crit Care. 2015;191:252–254.
  • Matthay MA, Anversa P, Bhattacharya J, et al. Cell therapy for lung diseases report from an NIH-NHLBI Workshop, November 13-14, 2012. Am J Resp Crit Care. 2013;188:370–375.
  • Serrano-Mollar A, Nacher M, Gay-Jordi G, et al. Intratracheal transplantation of alveolar type ii cells reverses bleomycin-induced lung fibrosis. Am J Resp Crit Care. 2007;176:1261–1268.
  • Tanaka K, Fujita T, Umezawa H, et al. Therapeutic effect of lung mixed culture-derived epithelial cells on lung fibrosis. Lab Invest. 2014;94:1247–1259.
  • Toonkel RL, Hare JM, Matthay MA, et al. Mesenchymal stem cells and idiopathic pulmonary fibrosis potential for clinical testing. Am J Resp Crit Care. 2013;188:133–140.

• A clinical approach of using MSCs in IPF treatment.

  • Zhou QL, Ye XL, Sun RW, et al. Differentiation of mouse induced pluripotent stem cells into alveolar epithelial cells in vitro for use in vivo. Stem Cell Transl Med. 2014;3:675–685.
  • Banerjee ER, Laflamme MA, Papayannopoulou T, et al. Human embryonic stem cells differentiated to lung lineage-specific cells ameliorate pulmonary fibrosis in a xenograft transplant mouse model. Plos One. 2012;7:21–25.
  • Lee SH, Lee EJ, Lee SY, et al. The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice. Exp Lung Res. 2014;40:117–125.
  • Barczyk M, Schmidt M, Mattoli S. Stem cell-based therapy in idiopathic pulmonary fibrosis. Stem Cell Rev Rep. 2015;11:598–620.
  • Borok Z, Foster MJ, Zabski SM, et al. Alveolar epithelial type I cells express sodium transport proteins. Am J Resp Crit Care. 1999;159:A467–A467.
  • Jeong JO, Han JW, Kim JM, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res. 2011;108:1340–1347.
  • Ma N, Gai H, Mei J, et al. Bone marrow mesenchymal stem cells can differentiate into type II alveolar epithelial cells in vitro. Cell Biol Int. 2011;35:1261–1266.
  • Banerjee ER, Laflamme MA, Papayannopoulou T, et al. Human embryonic stem cells differentiated to lung lineage-specific cells ameliorate pulmonary fibrosis in a xenograft transplant mouse model. Plos One. 2012;7:e33165.
  • Rafii R, Juarez M, Albertson T, et al. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis. 2013;5:48–73.
  • Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012;10:709–716.
  • Yan X, Liu Y, Han Q, et al. Injured microenvironment directly guides the differentiation of engrafted Flk-1(+) mesenchymal stem cell in lung. Exp Hematol. 2007;35:1466–1475.
  • Kurtz A. Mesenchymal stem cell delivery routes and fate. Int J Stem Cells. 2008;1:1–7.
  • Ghionzoli M, Cananzi M, Zani A, et al. Amniotic fluid stem cell migration after intraperitoneal injection in pup rats: implication for therapy. Pediatr Surg Int. 2010;26:79–84.
  • Yousefi F, Ebtekar M, Soleimani M, et al. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). Int Immunopharmacol. 2013;17:608–616.

•• Comparison between two main routes of cell delivery.

  • Conese M, Carbone A, Castellani S, et al. Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases. Cells Tissues Organs. 2013;197:445–473.
  • Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. P Natl Acad Sci USA. 2003;100:8407–8411.

•• This was the first study to show the ameliorative effects of MSCs in fibrotic lung injury.

  • Rojas M, Xu JG, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Resp Cell Mol. 2005;33:145–152.
  • Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007;179:1855–1863.
  • Zhao DC, Lei JX, Chen R, et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroentero. 2005;11:3431–3440.
  • Cargnoni A, Gibelli L, Tosini A, et al. Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant. 2009;18:405–422.
  • Moodley Y, Atienza D, Manuelpillai U, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol. 2009;175:303–313.
  • Tashiro J, Elliot SJ, Gerth DJ, et al. Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis, Translational Research. J Lab Clin Med. 2015;166(6):554–567.
  • Aguilar S, Scotton CJ, McNulty K, et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. Plos One. 2009;4:e8013.
  • Yamada M, Kubo H, Kobayashi S, et al. Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccharide-induced lung injury (vol 172, pg 1266, 2004). J Immunol. 2004;173:4755–4755.
  • Can A, Balci D. Isolation, culture, and characterization of human umbilical cord stroma-derived mesenchymal stem cells. Methods Mol Biol. 2011;698:51–62.
  • Coraux C, Nawrocki-Raby B, Hinnrasky J, et al. Embryonic stem cells generate airway epithelial tissue. Am J Resp Cell Mol. 2005;32:87–92.
  • Rippon HJ, Ali NN, Polak JM, et al. Initial observations on the effect of medium composition on the differentiation of murine embryonic stem cells to alveolar type II cells. Cloning Stem Cells. 2004;6:49–56.
  • Carbone A, Paracchini V, Castellani S, et al. Human amnion-derived cells: prospects for the treatment of lung diseases. Curr Stem Cell Res T. 2014;9:297–305.
  • Hodges RJ, Lim R, Jenkin G, et al. Amnion epithelial cells as a candidate therapy for acute and chronic lung injury. Stem Cells Int. 2012;2012. Article ID 709763, 7 pages. doi:10.1155/2012/709763
  • Kolonin MG, Evans KW, Mani SA, et al. Alternative origins of stroma in normal organs and disease. Stem Cell Res. 2012;8:312–323.
  • Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007;100:1249–1260.
  • Uji M, Nakada A, Nakamura T. Intravenous administration of adipose-derived stromal cells does not ameliorate bleomycin-induced lung injury in rats. Open J Regenerative Med. 2013;2:39–45.
  • Baek SJ, Kang SK, Ra JC. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med. 2011;43:596–603.
  • Mou HM, Zhao R, Sherwood R, et al. Generation of multipotent lung and airway progenitors from mouse escs and patient-specific cystic fibrosis iPSCs. Cell Stem Cell. 2012;10:385–397.
  • Bertoncello I, McQualter JL. Lung stem cells: do they exist?. Respirology. 2013;18:587–595.
  • Spees JL, Pociask DA, Sullivan DE, et al. Engraftment of bone marrow progenitor cells in a rat model of asbestos-induced pulmonary fibrosis. Am J Resp Crit Care. 2007;176:385–394.
  • Martin J, Helm K, Ruegg P, et al. Adult lung side population cells have mesenchymal stem cell potential. Cytotherapy. 2008;10:140–151.
  • Collins JJP, Thebaud B. Lung mesenchymal stromal cells in development and disease: to serve and protect?. Antioxid Redox Sign. 2014;21:1849–1862.
  • Foronjy RF, Majka SM. The potential for resident lung mesenchymal stem cells to promote functional tissue regeneration: understanding microenvironmental cues. Cells. 2012;1:874.
  • Yamamoto Y, Baldwin HS, Prince LS. Endothelial differentiation by multipotent fetal mouse lung mesenchymal cells. Stem Cells Dev. 2012;21:1455–1465.
  • Gong XM, Sun ZR, Cui D, et al. Isolation and characterization of lung resident mesenchymal stem cells capable of differentiating into alveolar epithelial type II cells. Cell Biol Int. 2014;38:405–411.
  • Chapman HA, Li XP, Alexander JP, et al. Integrin alpha 6 beta 4 identifies an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest. 2011;121:2855–2862.
  • Hegab AE, Ha VL, Gilbert JL, et al. Novel stem/progenitor cell population from murine tracheal submucosal gland ducts with multipotent regenerative potential. Stem Cells. 2011;29:1283–1293.
  • Kumar Pooja A, Hu Y, Yamamoto Y, et al. Distal airway stem cells yield alveoli in vitro and during lung regeneration following h1n1 influenza infection. Cell. 2011;147:525–538.
  • Smadja DM, Dorfmuller P, Guerin CL, et al. Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. Thromb Haemost. 2014;112:1002–1013.
  • Barratt S, Millar A. Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis. Qjm-Int J Med. 2014;107:515–519.
  • Malli F, Koutsokera A, Paraskeva E, et al. Endothelial progenitor cells in the pathogenesis of idiopathic pulmonary fibrosis: an evolving concept. Plos One. 2013;8:e53658.
  • Smadja DM, Mauge L, Nunes H, et al. Imbalance of circulating endothelial cells and progenitors in idiopathic pulmonary fibrosis. Angiogenesis. 2013;16:147–157.
  • How C-K, Chien Y, Yang K-Y, et al. Induced pluripotent stem cells mediate the release of interferon gamma-induced protein 10 and alleviate bleomycin-induced lung inflammation and fibrosis. Shock. 2013;39:261–270.
  • Yunt ZX, Mohning MP, Barthel L, et al. Kinetics of the angiogenic response in lung endothelium following acute inflammatory injury with bleomycin. Exp Lung Res. 2014;40:415–425.
  • Silva JD, Paredes BD, Araujo IM, et al. Effects of bone marrow-derived mononuclear cells from healthy or acute respiratory distress syndrome donors on recipient lung-injured mice. Crit Care Med. 2014;42:E510–E524.
  • Kean TJ, Lin P, Caplan AI, et al. MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int. 2013;2013:13.
  • Sosnowski TR, Kurowska A, Butruk B, et al. Spraying of cell colloids in medical atomizers. Chem Eng Trans. 2013;32:2257–2262.
  • Petersen TH, Calle EA, Niklason LE. Strategies for lung regeneration. Mater Today. 2011;14:196–201.
  • Kardia E, Yusoff NM, Zakaria Z, et al. Aerosol-based delivery of fibroblast cells for treatment of lung diseases. J Aerosol Med Pulm Drug Deliv. 2014;27:30–34.

• This is about the ways to aerosolize cells for pulmonary delivery.

  • Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683–691.
  • Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683–692.
  • Sung DK, Chang YS, Ahn SY, et al. Optimal route for human umbilical cord blood-derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury: gene expression profiles and histopathology. Plos One. 2015;10:e0135574.
  • Abreu SC, Antunes MA, Maron-Gutierrez T, et al. Bone marrow mononuclear cell therapy in experimental allergic asthma: intratracheal versus intravenous administration. Resp Physiol Neurobi. 2013;185:615–624.
  • Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–2286.

• This clinical trial demonstrated the safety of MSC administration and range of administered doses in Acute Myocardial Infarction.

  • Kumamoto M, Nishiwaki T, Matsuo N, et al. Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury. Eur Respir J. 2009;34:740–748.
  • Huleihel L, Levine M, Rojas M. The potential of cell-based therapy in lung diseases. Expert Opin Biol Th. 2013;13:1429–1440.
  • Gazdhar A, Susuri N, Hostettler K, et al. HGF expressing stem cells in usual interstitial pneumonia originate from the bone marrow and are antifibrotic. Plos One. 2013;8:e65453.
  • Yunt Z, Mohning M, Barthel L, et al. Kinetics of the angiogenic response in lung endothelium following acute inflammatory injury with bleomycin. Exp Lung Res. 2014;40:415–425.
  • Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. Plos Med. 2009;6:221–231.
  • Suzuki T, Mayhew C, Sallese A, et al. Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am J Resp Crit Care. 2014;189:183–193.
  • Herberts CA, Kwa MSG, Hermsen HPH. Risk factors in the development of stem cell therapy. J Transl Med. 2011;9:29.
  • Ilic N, Atkinson K. Manufacturing and use of human placenta-derived mesenchymal stromal cells for phase I clinical trials: establishment and evaluation of a protocol. Vojnosanit Pregl. 2014;71:651–659.
  • Tan JL, Chan ST, Wallace EM, et al. Human amnion epithelial cells mediate lung repair by directly modulating macrophage recruitment and polarization. Cell Trans. 2014;23:319–328.
  • Lazarus HM. Acute leukemia in adults: novel allogeneic transplant strategies. Hematology. 2012;17:S47–S51.
  • Fang TL, Lineaweaver WC, Sailes FC, et al. Clinical application of cultured epithelial autografts on acellular dermal matrices in the treatment of extended burn injuries. Ann Plas Surg. 2014;73:509–515.
  • Grupp SA, Dvorak CC, Nieder ML, et al. Children’s Oncology Group’s 2013 blueprint for research: Stem cell transplantation. Pediatr Blood Cancer. 2013;60:1044–1047.
  • Smith AR, Wagner JE. Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Brit J Haematol. 2009;147:246–261.
  • Harrington H, Cato P, Salazar F, et al. Immunocompetent 3D model of human upper airway for disease modeling and in vitro drug evaluation. Mol Pharm. 2014;11:2082–2091.
  • Wagner DE, Bonvillain RW, Jensen T, et al. Can stem cells be used to generate new lungs? Ex vivo lung bioengineering with decellularized whole lung scaffolds. Respirology. 2013;18:895–911.
  • Mendez JJ, Ghaedi M, Steinbacher D, et al. Epithelial cell differentiation of human mesenchymal stromal cells in decellularized lung scaffolds. Tissue Eng. 2014;20:1735–1746.
  • Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochem Cell Biol. 2015;93:159–170.
  • Corner BS, Ba M, Singer CA, et al. Epigenetic targets for novel therapies of lung diseases. Pharmacol Therapeut. 2015;147:91–110.
  • Yang IV, Schwartz DA. Epigenetics of idiopathic pulmonary fibrosis. Translational Res. 2015;165:48–60.
  • Zimmermann JA, McDevitt TC. Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion. Cytotherapy. 2014;16:331–345.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.